ISPAD

Press Release: TZIELD® Phase 3 data presented at ISPAD shows potential to slow the progression of Stage 3 type 1 diabetes in newly diagnosed children and adolescents; full data simultaneously published in The NEJM

Retrieved on: 
Wednesday, October 18, 2023
Medical Affairs Bureau, AUC, Ageing, Yale School of Medicine, Endocrinology, Conference, Diabetes, Acquisition, General Medicine Faculty of RostGMU (Rostov State Medical University), PROTECT, LSM, Numerical, Growth, Disease, Clinical trial, The New England Journal of Medicine, C-peptide, Sanofi, Safety, T1D, ISPAD, Patient, Pharmaceutical industry, Medical imaging, Management, Medicine

New data from TZIELD’s (teplizumab-mzwv) PROTECT Phase 3 trial were presented today at the 49th Annual ISPAD Conference, in Rotterdam, The Netherlands.

Key Points: 
  • New data from TZIELD’s (teplizumab-mzwv) PROTECT Phase 3 trial were presented today at the 49th Annual ISPAD Conference, in Rotterdam, The Netherlands.
  • The full data set has been simultaneously published in The New England Journal of Medicine .
  • This significant difference indicates the potential of TZIELD to slow the progression of Stage 3 type 1 diabetes in this population.
  • While the study’s key secondary endpoints did not meet statistical significance, numerical trends favoring TZIELD were seen in relevant clinical parameters.

JDRF Encouraged by Results of PROTECT Clinical Trial

Retrieved on: 
Wednesday, October 18, 2023
International Society for Pediatric and Adolescent Diabetes, JDRF, PROTECT, Research, Disease, Clinical trial, Risk, The New England Journal of Medicine, C-peptide, Sanofi, International Society, T1D, ISPAD, Vaccine, Pharmaceutical industry

The trial investigated whether TZIELD can slow the loss of beta cells and preserve beta cell function, as measured by C-peptide, in newly diagnosed (stage 3 T1D) children and adolescents ages 8-17.

Key Points: 
  • The trial investigated whether TZIELD can slow the loss of beta cells and preserve beta cell function, as measured by C-peptide, in newly diagnosed (stage 3 T1D) children and adolescents ages 8-17.
  • The results were also published today in the New England Journal of Medicine .
  • "Preserving beta cell function in individuals diagnosed with type 1 diabetes is a critical step towards cures and, crucially, is helpful in type 1 diabetes management," said Sanjoy Dutta, Ph.D., JDRF chief scientific officer.
  • JDRF appreciates Provention Bio and Sanofi's ongoing commitment to individuals diagnosed with type 1 diabetes and applauds all efforts aimed at finding cures and improving therapies for this population."

Human Rights Congress for Bangladesh Minorities Holds Press Conference in D.C. Bangladesh Consul General Attends

Retrieved on: 
Tuesday, November 1, 2022
Human rights, Vacuum, International Crimes Tribunal of Bangladesh Timeline, Congress, Violence, General officer, Journalist, Government, Legislature, Policy, Resolution, Bangladesh Minority Janata Party, United States House Committee on Foreign Affairs, Physician, Press club, Provisional Government of Bangladesh, Executive, SUNY, Pakistan Army Medical Corps, Bangladeshis, Assistant Secretary of Defense for Indo-Pacific Security Affairs, Genocide, International Crimes Tribunal, Crime, Jamaat-e-Islami, Woman, Pakistan Army, Freedom, Columbia University, Expression, GIIS, Communication, ISPAD, National Press Club (Pakistan), Tessa Rajak, Film, Pacific Ocean

WASHINGTON, Nov. 1, 2022 /PRNewswire/ -- As more and more lawmakers join in support of the resolution, The Human Rights Congress for Bangladesh Minorities (HRCBM) held a press conference at the National Press Club last Friday. The conference was attended by members of the media, human rights activists, academics, entrepreneurs, members of the Bangladeshi diaspora community and Bangladesh's consul general to Florida, to discuss the recent introduction of the bipartisan H.Res. 1430 by Congressman Steve Chabot, Ranking Member of the House Foreign Affairs Committee's Subcommittee on Asia and the Pacific, and Co-Chair of the Bangladesh Caucus and co-sponsored by Congressman Ro Khanna (D-CA), Congresswoman Katie Porter (D-CA) and Congressman Tom Malinowski (D-NJ).

Key Points: 
  • WASHINGTON, Nov. 1, 2022 /PRNewswire/ -- As more and more lawmakers join in support of the resolution, The Human Rights Congress for Bangladesh Minorities (HRCBM) held a press conference at the National Press Club last Friday.
  • The conference was attended by members of the media, human rights activists, academics, entrepreneurs, members of the Bangladeshi diaspora community and Bangladesh's consul general to Florida, to discuss the recent introduction of the bipartisan H.Res.
  • The Bangladesh government started to prosecute war criminals who collaborated with the Pakistan army and the Government of Bangladesh formed the International Crimes Tribunal of Bangladesh.
  • Razzak Baloch, Organizer, Baloch Human Rights, condemned the Pakistani Army for its genocide in Bangladesh in 1971.

JDRF Announces Launch of global Type 1 Diabetes Index

Retrieved on: 
Wednesday, September 21, 2022
Leona, International Diabetes Federation, Disability, Volunteering, Time, Incidence, Efficiency, Diet, Twitter, Risk, Prevalence, Publication, NEW, CDN, Insulin, Industry, Diabetes, Endocrinology, Pancreas, Government, Mental health, Vertex Pharmaceuticals, American Association of Clinical Endocrinologists, JDRF, Technology, Quality of life, Public health, Life, CGMS-A, The Lancet, International Society, Diagnosis, IDF, Heart, Research, GLOBE, The Leona M. and Harry B. Helmsley Charitable Trust, Education, ISPAD, International Society for Pediatric and Adolescent Diabetes, Death, Pump, Pharmaceutical industry, Management, Medical device, Child, Index, Facebook, Instagram, T1D, Lilly

TORONTO and NEW YORK, Sept. 21, 2022 (GLOBE NEWSWIRE) -- JDRF, the leading global type 1 diabetes (T1D) research and advocacy organization, announces the launch of the Type 1 Diabetes Index (T1D Index).

Key Points: 
  • TORONTO and NEW YORK, Sept. 21, 2022 (GLOBE NEWSWIRE) -- JDRF, the leading global type 1 diabetes (T1D) research and advocacy organization, announces the launch of the Type 1 Diabetes Index (T1D Index).
  • The T1D Index and accompanying research has been published in the world leading diabetes and endocrinology medical journal, The Lancet Diabetes & Endocrinology.
  • This is why I am so proud that significant progress has been made to understand T1Ds global impact through the T1D Index.
  • It is a collaborative development by JDRF, Life for a Child , International Society for Pediatric and Adolescent Diabetes (ISPAD) , International Diabetes Federation (IDF), and Beyond Type 1 .

JDRF Announces Launch of Global Type 1 Diabetes Index

Retrieved on: 
Wednesday, September 21, 2022
Leona, International Diabetes Federation, Disability, Volunteering, Incidence, Efficiency, Diet, Twitter, Risk, Prevalence, Publication, NEW, Insulin, Industry, Abbott, Endocrinology, Pancreas, Government, Mental health, Vertex Pharmaceuticals, American Association of Clinical Endocrinologists, JDRF, Technology, Quality of life, Public health, Life, CGMS-A, International Society, Diagnosis, IDF, Heart, Research, Awareness, Multimedia, The Leona M. and Harry B. Helmsley Charitable Trust, Education, ISPAD, View, International Society for Pediatric and Adolescent Diabetes, Death, Pump, Pharmaceutical industry, Medical device, Seaweed, Child, Index, Facebook, Instagram, T1D, Lilly

NEW YORK, Sept. 21, 2022 /PRNewswire/ -- JDRF, the leading global type 1 diabetes (T1D) research and advocacy organization, announces the launch of the Type 1 Diabetes Index (T1D Index). The T1D Index is a first-of-its-kind data simulation tool that measures the human and public health impact of the T1D crisis in every country across the globe. Until now, there have been wide gaps in the data about the incidence and impact of T1D. Leveraging data and insights from the T1D Index can help change the lives of people living with T1D by identifying attainable country-by-country interventions including timely diagnosis, accessible care and funding research that could lead to cures.

Key Points: 
  • The first-of-its-kind index will raise awareness of the burden and unmet need of people living with type 1 diabetes around the world.
  • NEW YORK, Sept. 21, 2022 /PRNewswire/ -- JDRF , the leading global type 1 diabetes (T1D) research and advocacy organization, announcesthe launch of the Type 1 Diabetes Index (T1D Index).The T1D Index is afirst-of-its-kind data simulationtool that measures the human and public health impact of the T1D crisis in every country across the globe.
  • The T1DIndex and accompanying research has been published in the leading diabetes and endocrinology medical journal, The Lancet Diabetes &Endocrinology.
  • Itis a collaborative development by JDRF, Life for a Child , International Society for Pediatric and Adolescent Diabetes (ISPAD) , International Diabetes Federation (IDF), and Beyond Type 1 .

JDRF Announces Launch of Global Type 1 Diabetes Index

Retrieved on: 
Wednesday, September 21, 2022
Leona, International Diabetes Federation, Disability, Volunteering, Incidence, Efficiency, Diet, Twitter, Risk, Prevalence, Publication, NEW, Insulin, Industry, Abbott, Endocrinology, Pancreas, Government, Mental health, Vertex Pharmaceuticals, American Association of Clinical Endocrinologists, JDRF, Technology, Quality of life, Public health, Life, CGMS-A, International Society, Diagnosis, IDF, Heart, Research, Awareness, The Leona M. and Harry B. Helmsley Charitable Trust, Education, ISPAD, International Society for Pediatric and Adolescent Diabetes, Death, Pump, Pharmaceutical industry, Medical device, Seaweed, Child, Index, Facebook, Instagram, T1D, Lilly

NEW YORK, Sept. 21, 2022 /PRNewswire/ -- JDRF, the leading global type 1 diabetes (T1D) research and advocacy organization, announces the launch of the Type 1 Diabetes Index (T1D Index). The T1D Index is a first-of-its-kind data simulation tool that measures the human and public health impact of the T1D crisis in every country across the globe. Until now, there have been wide gaps in the data about the incidence and impact of T1D. Leveraging data and insights from the T1D Index can help change the lives of people living with T1D by identifying attainable country-by-country interventions including timely diagnosis, accessible care and funding research that could lead to cures.

Key Points: 
  • The first-of-its-kind index will raise awareness of the burden and unmet need of people living with type 1 diabetes around the world.
  • NEW YORK, Sept. 21, 2022 /PRNewswire/ -- JDRF , the leading global type 1 diabetes (T1D) research and advocacy organization, announcesthe launch of the Type 1 Diabetes Index (T1D Index).The T1D Index is afirst-of-its-kind data simulationtool that measures the human and public health impact of the T1D crisis in every country across the globe.
  • The T1DIndex and accompanying research has been published in the leading diabetes and endocrinology medical journal, The Lancet Diabetes &Endocrinology.
  • Itis a collaborative development by JDRF, Life for a Child , International Society for Pediatric and Adolescent Diabetes (ISPAD) , International Diabetes Federation (IDF), and Beyond Type 1 .

A new analysis that supports the effect of the diabetes vaccine Diamyd® will be presented at a scientific conference on 13 October

Retrieved on: 
Thursday, September 23, 2021
ISPAD, Clinical trial, Diamyd Medical, International Society for Pediatric and Adolescent Diabetes, Hyperglycemia, GAD65, Society, Hannelius, ASHG, Diabetes, Patient, Type 1, Glycated hemoglobin, Eli Lilly and Company, Pediatrics, Continuous glucose monitor, International Society of Sculptors, Painters and Gravers, CEO, Blood, Meta-analysis, Company, Adolescence, Congress, Uppsala University Hospital, Human genetics, CGM, Hypoglycemia, Insulin, IIB, HLA, Nasdaq, EASD, Regeneration, Pharmaceutical industry

The analysis is based on data from Continuous Glucose Montitoring (CGM) and will be presented by Professor Johnny Ludvigsson, Principal Investigator of the clinical trial DIAGNODE-2.

Key Points: 
  • The analysis is based on data from Continuous Glucose Montitoring (CGM) and will be presented by Professor Johnny Ludvigsson, Principal Investigator of the clinical trial DIAGNODE-2.
  • Complete results will be submitted for publication in a scientific journal later this year.
  • The diabetes vaccine Diamyd is an antigen-specific immunotherapy for the preservation of endogenous insulin production.
  • A vaccine manufacturing facility is being set up in Ume for the manufacture of recombinant GAD65, the active ingredient in the therapeutic diabetes vaccine Diamyd.

A new analysis that supports the effect of the diabetes vaccine Diamyd® will be presented at a scientific conference on 13 October

Retrieved on: 
Thursday, September 23, 2021
ISPAD, Clinical trial, Diamyd Medical, International Society for Pediatric and Adolescent Diabetes, Hyperglycemia, GAD65, Society, Hannelius, ASHG, Diabetes, Patient, Type 1, Glycated hemoglobin, Eli Lilly and Company, Pediatrics, Continuous glucose monitor, International Society of Sculptors, Painters and Gravers, CEO, Blood, Meta-analysis, Company, Adolescence, Congress, Uppsala University Hospital, Human genetics, CGM, Hypoglycemia, Insulin, IIB, HLA, Nasdaq, EASD, Regeneration, Pharmaceutical industry

The analysis is based on data from Continuous Glucose Montitoring (CGM) and will be presented by Professor Johnny Ludvigsson, Principal Investigator of the clinical trial DIAGNODE-2.

Key Points: 
  • The analysis is based on data from Continuous Glucose Montitoring (CGM) and will be presented by Professor Johnny Ludvigsson, Principal Investigator of the clinical trial DIAGNODE-2.
  • Complete results will be submitted for publication in a scientific journal later this year.
  • The diabetes vaccine Diamyd is an antigen-specific immunotherapy for the preservation of endogenous insulin production.
  • A vaccine manufacturing facility is being set up in Ume for the manufacture of recombinant GAD65, the active ingredient in the therapeutic diabetes vaccine Diamyd.